The Association of British Clinical Diabetologists

Posters Spring 2018

Read more about Posters Spring 2018
Log in or register to post comments

Association of British Clinicial Diabetologists
Spring Meeting
Grand Central Hotel, Glasgow
23rd & 24th May 2018

POSTERS FOR ONLINE VIEWING

Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings

Read more about Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings

Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes

Read more about Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes

Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D

Read more about Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D

Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study

Read more about Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study

Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks

Read more about Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks

Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials

Read more about Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials

Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients

Read more about Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients

World travel with Type-1 diabetes

Read more about World travel with Type-1 diabetes

Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial

Read more about Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial

Subscribe to The Association of British Clinical Diabetologists